Form 4: Supernus Pharmaceuticals Director Acquires Stock Options and Restricted Stock Units

Director Frederick M. Hudson reports acquisition of stock options and restricted stock units in Supernus Pharmaceuticals.

Summary

• On February 19, 2025, Frederick M. Hudson, a director of Supernus Pharmaceuticals, acquired 7,296 stock options with an exercise price of $33.52, vesting on February 19, 2026 and expiring on February 19, 2035.
• Hudson also acquired 4,475 restricted stock units (RSUs) that will be settled in common stock upon vesting on February 19, 2026.
• Following these transactions, Hudson directly owns 48,395 shares of common stock, 7,296 stock options, and 4,475 restricted stock units.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard SEC filing reporting insider transactions. The acquisition of shares and options could be interpreted as a positive signal, but it's not definitively bullish.

Positives

• The acquisition of stock options and restricted stock units by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the ownership changes of company insiders.

Stakeholder Impact

• The acquisition of stock options and restricted stock units by a director may have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

Supernus Pharmaceuticals, Director, Stock Options, Restricted Stock Units, Beneficial Ownership, Form 4, SUPN